Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab ...

The Ovarian Cancer Diagnostics Market is estimated to reach at a CAGR of 6.8% during the forecast period (2024-2031). The Ovarian Cancer Diagnostics Market is rapidly growing due to rising awareness, ...

AbbVie is sprinting beyond its Humira dependency by banking on rising stars Skyrizi and Rinvoq, which are smashing sales ...

Broad effectiveness forms part of Genmab’s argument that Rina-S can improve on AbbVie’s Elahere, an approved ADC against the same target. AbbVie has sued Genmab over Rina-S, accusing the ...

Results of the trial, which evaluated the efficacy and safety of mirvetuximab soravtansine-gynx (Elahere, AbbVie), were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly necessities. AbbVie ( ABBV 0.02%) is one of the best. It outperformed the ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer patients, according to results from a confirmatory late-stage trial of the ...